Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide

NCT01604031 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL: B-CLL Vaccine
DRUG: Lenalidomide

Sponsor

Baylor College of Medicine

Collaborators

[object Object]
[object Object]